| 2026-02-12 |
Mateon Therapeutics |
Oncotelic Therapeutics, Inc. and Sapu Bioscience Expand International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway oncotelic.com ↗ |
| 2025-03-25 |
Mateon Therapeutics |
Oncotelic Therapeutics Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2, Highlights Findings at SWCR 2025 Conference oncotelic.com ↗ |
| 2023-08-23 |
Mateon Therapeutics |
Sapu BioScience and Cromos Pharma initiating P201 - A Registrational trial for OT-101 in Pancreatic Cancer oncotelic.com ↗ |
| 2023-01-25 |
Mateon Therapeutics |
Oncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer oncotelic.com ↗ |
| 2022-11-08 |
Mateon Therapeutics |
Oncotelic Initiates Clinical Trials Evaluating OT-101 against Pediatric Gliomas oncotelic.com ↗ |
| 2022-10-12 |
Mateon Therapeutics |
Oncotelic Awarded BARDA Funding for Development of OT-101 for long COVID oncotelic.com ↗ |
| 2022-07-12 |
Mateon Therapeutics |
Oncotelic Announces Presentation of P001- OT-101 Phase 1/2 Trial in Pancreatic Cancer oncotelic.com ↗ |
| 2022-06-15 |
Mateon Therapeutics |
Oncotelic Provides Update on OT-101 at the 2022 BIO International Convention oncotelic.com ↗ |
| 2022-05-25 |
Mateon Therapeutics |
Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201) oncotelic.com ↗ |
| 2021-12-01 |
Mateon Therapeutics |
Oncotelic Initiates Phase 2 Trial Evaluating OT-101 in Combination with KEYTRUDA® for Mesothelioma oncotelic.com ↗ |
| 2021-11-23 |
Mateon Therapeutics |
ONCOTELIC ANNOUNCES POSITIVE TOPLINE DATA FOR OT-101 C001 COVID STUDY oncotelic.com ↗ |
| 2021-11-16 |
Mateon Therapeutics |
Oncotelic Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination Trial in Solid Tumor Cancers oncotelic.com ↗ |
| 2021-10-20 |
Mateon Therapeutics |
ONCOTELIC ANNOUNCES UPDATE ON THE OT-101 CLINICAL PROGRAMS INCLUDING C001 COVID STUDY oncotelic.com ↗ |
| 2021-04-19 |
Mateon Therapeutics |
ONCOTELIC THERAPEUTICS, INC. ANNOUNCED SYNERGY BETWEEN OT-101 AND IL-2 (PROLEUKIN) AT AACR-2021 oncotelic.com ↗ |
| 2021-03-15 |
Mateon Therapeutics |
MATEON ANNOUNCES INITIATION OF PHASE 1B CLINICAL TRIAL ON OT-101/IL-2 COMBINATION THERAPY FOR SOLID TUMORS oncotelic.com ↗ |
| 2020-09-21 |
Mateon Therapeutics |
OT-101 PRESENTATION AT PHARMA FORUM 2020 oncotelic.com ↗ |
| 2020-07-09 |
Mateon Therapeutics |
Company expands its management team to accelerate the commercialization and development of OT-101 for COVID-19 oncotelic.com ↗ |
| 2020-06-29 |
Mateon Therapeutics |
MATEON ANNOUNCES $2 MILLION FINANCING WITH GOLDEN MOUNTAIN PARTNERS TO CONDUCT CLINICAL TRIAL OF OT-101 AGAINST COVID19 oncotelic.com ↗ |
| 2020-06-24 |
Mateon Therapeutics |
MATEON IS SELECTED BY IBM WATSON HEALTH FOR THE USE OF IBM CLINICAL DEVELOPMENT SOLUTION AT NO COST FOR PHASE II CLINICAL TRIAL OF OT-101 FOR COVID-19 oncotelic.com ↗ |
| 2020-06-23 |
Mateon Therapeutics |
Mateon Therapeutics Selects IQVIA for its Randomized, Controlled, Multi-Center Clinical Study to Test OT-101 as a Treatment for COVID-19 Patients oncotelic.com ↗ |
| 2020-06-10 |
Mateon Therapeutics |
Mateon Announces Achievement of Milestone Under Licensing of OT-101/IL-2 Combination to Autotelic BIO oncotelic.com ↗ |
| 2020-06-01 |
Mateon Therapeutics |
Mateon Provides Update on OT-101 oncotelic.com ↗ |
|